Suven Life Sciences gets product patents from Canada, India
New Delhi: Suven Life Sciences has secured a product patent each from Canada and India for treatment of neurodegenerative disorders.
These patents are valid through 2034 and 2028, respectively, the company said in a BSE filing.
"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
Suven Life said the granted claims of the patents are being developed as therapeutic agents and useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Parkinson, and Schizophrenia.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd